Bridgebio Pharma Inc. Stock
€26.63
Your prediction
Bridgebio Pharma Inc. Stock
Pros and Cons of Bridgebio Pharma Inc. in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.A preliminary examination of the financials of Bridgebio Pharma Inc. suggests some areas of potential concern, along with a few positive indicators. Balance sheets from the last three years reveal a steady increase in total assets, with a significant jump between 2020 and 2021. However, the company has also been accumulating a sizeable amount of long-term debt, exceeding its total assets.
Some positives can indeed be seen in the company's financials. These mainly emanate from the increasing trend in total assets and the steady accumulation of cash and short-term investments. There's an evident growth in company's total assets, from $703M in 2020 to over $1B in 2021 and then a bit of a drop in 2022 back to $623M. This indicates the company's ability to generate wealth, which is a good sign for potential investors.
Additionally, a significant portion of its assets is in cash and short-term investments. Liquid assets are crucial for any business as they can be quickly converted into cash to cover immediate expenses and liabilities. Over the years, the company's short-term investment holdings, along with the cash, have been growing; from $607M in 2020 to a significant increase in 2021 to $787M. This might act as a safety net for the company given any market disruptions.